GLMD
Price
$1.99
Change
+$0.01 (+0.51%)
Updated
Jul 25 closing price
Capitalization
4.49M
4 days until earnings call
XBIO
Price
$3.60
Change
-$0.04 (-1.10%)
Updated
Jul 25 closing price
Capitalization
5.56M
Interact to see
Advertisement

GLMD vs XBIO

Header iconGLMD vs XBIO Comparison
Open Charts GLMD vs XBIOBanner chart's image
Galmed Pharmaceuticals
Price$1.99
Change+$0.01 (+0.51%)
Volume$414.67K
Capitalization4.49M
Xenetic Biosciences
Price$3.60
Change-$0.04 (-1.10%)
Volume$88.58K
Capitalization5.56M
GLMD vs XBIO Comparison Chart in %
Loading...
GLMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GLMD vs. XBIO commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GLMD is a StrongBuy and XBIO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (GLMD: $1.99 vs. XBIO: $3.60)
Brand notoriety: GLMD and XBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GLMD: 121% vs. XBIO: 94%
Market capitalization -- GLMD: $4.49M vs. XBIO: $5.56M
GLMD [@Biotechnology] is valued at $4.49M. XBIO’s [@Biotechnology] market capitalization is $5.56M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GLMD’s FA Score shows that 0 FA rating(s) are green whileXBIO’s FA Score has 1 green FA rating(s).

  • GLMD’s FA Score: 0 green, 5 red.
  • XBIO’s FA Score: 1 green, 4 red.
According to our system of comparison, both GLMD and XBIO are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GLMD’s TA Score shows that 4 TA indicator(s) are bullish while XBIO’s TA Score has 3 bullish TA indicator(s).

  • GLMD’s TA Score: 4 bullish, 4 bearish.
  • XBIO’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, GLMD is a better buy in the short-term than XBIO.

Price Growth

GLMD (@Biotechnology) experienced а +8.74% price change this week, while XBIO (@Biotechnology) price change was -1.54% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.62%. For the same industry, the average monthly price growth was +17.39%, and the average quarterly price growth was +28.36%.

Reported Earning Dates

GLMD is expected to report earnings on Nov 10, 2025.

XBIO is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (+7.62% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XBIO($5.56M) has a higher market cap than GLMD($4.49M). XBIO YTD gains are higher at: -9.687 vs. GLMD (-37.618). XBIO has higher annual earnings (EBITDA): -3.88M vs. GLMD (-6.07M). GLMD has more cash in the bank: 15.7M vs. XBIO (5.16M). GLMD has less debt than XBIO: GLMD (41K) vs XBIO (153K). XBIO has higher revenues than GLMD: XBIO (2.58M) vs GLMD (0).
GLMDXBIOGLMD / XBIO
Capitalization4.49M5.56M81%
EBITDA-6.07M-3.88M156%
Gain YTD-37.618-9.687388%
P/E Ratio0.02N/A-
Revenue02.58M-
Total Cash15.7M5.16M304%
Total Debt41K153K27%
FUNDAMENTALS RATINGS
GLMD vs XBIO: Fundamental Ratings
GLMD
XBIO
OUTLOOK RATING
1..100
7497
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
18
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
6059
P/E GROWTH RATING
1..100
96100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XBIO's Valuation (18) in the Biotechnology industry is in the same range as GLMD (35) in the Pharmaceuticals Other industry. This means that XBIO’s stock grew similarly to GLMD’s over the last 12 months.

XBIO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as GLMD (100) in the Pharmaceuticals Other industry. This means that XBIO’s stock grew similarly to GLMD’s over the last 12 months.

GLMD's SMR Rating (96) in the Pharmaceuticals Other industry is in the same range as XBIO (97) in the Biotechnology industry. This means that GLMD’s stock grew similarly to XBIO’s over the last 12 months.

XBIO's Price Growth Rating (59) in the Biotechnology industry is in the same range as GLMD (60) in the Pharmaceuticals Other industry. This means that XBIO’s stock grew similarly to GLMD’s over the last 12 months.

GLMD's P/E Growth Rating (96) in the Pharmaceuticals Other industry is in the same range as XBIO (100) in the Biotechnology industry. This means that GLMD’s stock grew similarly to XBIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GLMDXBIO
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 3 days ago
85%
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 5 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
GLMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PPBI22.571.41
+6.66%
Pacific Premier Bancorp
HDSN8.530.25
+3.08%
Hudson Technologies
ABLV1.090.02
+1.86%
Able View Global
NTRP3.970.04
+1.07%
NextTrip
ALLY38.540.16
+0.42%
Ally Financial